Loading…
for educational and safety purposes
Cabergoline and Pramipexole both come up in the same conversations. Cabergoline: Cabergoline is a long-acting, ergot-derived dopamine agonist that acts mainly at the dopamine D2 receptor. Pramipexole: Pramipexole is a non-ergoline dopamine agonist used mainly to treat Parkinson's disease and restless legs syndrome.
Cabergoline is a long-acting, ergot-derived dopamine agonist that acts mainly at the dopamine D2 receptor. It is used chiefly to treat conditions of excess prolactin, especially prolactin-secreting pituitary tumors (prolactinomas), and is also used in Parkinson disease and acromegaly. Because of its long duration of action it is usually taken only once or twice a week.
Pramipexole is a non-ergoline dopamine agonist used mainly to treat Parkinson's disease and restless legs syndrome. It works by directly stimulating dopamine receptors in the brain, with a preference for the D3 subtype, standing in for the dopamine signalling that is lost in Parkinson's disease. First approved in the United States in 1997 and sold under names such as Mirapex, Mirapexin and Sifrol, it is available as immediate-release and extended-release tablets and has also been studied off-label for depression.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist
agonist
agonist
agonist
modulates
agonist
activates
agonist
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.